THE ANALYSIS STUDY OF ASSOCIATION OF TYPE 2 DIABETES MELLITUS AND SKIN CANCER : A COMPREHENSIVE SYSTEMATIC REVIEW

Authors

  • Tia Alviani Juwita Faculty of Medicine, HKBP Nommensen University, Medan, Indonesia
  • Indah Sari Siregar Faculty of Medicine, North Sumatera University, Medan, Indonesia

DOI:

https://doi.org/10.61841/xdw7fm80

Keywords:

Diabetes, skin cancer, correlation, incidence, NMSC

Abstract

Background: The correlation between type 2 diabetes and skin cancer has been established, with elevated blood glucose levels and increased insulin levels associated with a higher risk of certain malignancies, such as nonmelanoma skin cancer. However, the impact of insulin therapy on cancer risk in individuals with type 2 diabetes is generally not significant. Understanding this correlation can help develop effective strategies for managing both conditions.

Methods: Following PRISMA 2020 guidelines, this systematic review concentrated on full-text English literature published between 2014 and 2024. Editorials and review articles that appeared in the same journal as the submission were not accepted without a DOI. A number of websites, including ScienceDirect, PubMed, and SagePub, were utilized to gather the literature.

Result: The study looked at more than 100 publications using reputable sources including Science Direct, SagePub, and PubMed. After it was decided that eight publications needed greater investigation, a more extensive review of the entire literature was carried out.

Conclusion: The incidence of skin cancer in diabetic individuals is higher in those aged 60 and older, with males more likely to develop non-melanoma skin cancer (NMSC) and melanoma. Risk factors include sex, comorbidities, immunosuppression status, and socioeconomic status. Insulin therapy can lower the risk of NMSC, but further studies are needed to understand differences in incidence.

References

Massouh, N., Jaffa, A. A., & Jaffa, M. A. (2024). Role of Insulin Use and Social Determinants of Health on Non-melanoma Skin Cancer: Results From the Behavioral Risk Factor Surveillance System. Cancer control : journal of the Moffitt Cancer Center, 31, 10732748241249896. https://doi.org/10.1177/10732748241249896

Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010). Diabetes and cancer: a consensus report. Diabetes care, 33(7), 1674–1685. https://doi.org/10.2337/dc10-0666

Sasazuki, S., Charvat, H., Hara, A., Wakai, K., Nagata, C., Nakamura, K., Tsuji, I., Sugawara, Y., Tamakoshi, A., Matsuo, K., Oze, I., Mizoue, T., Tanaka, K., Inoue, M., Tsugane, S., & Research Group for the Development and Evaluation of Cancer Prevention Strategies in Japan (2013). Diabetes mellitus and cancer risk: pooled analysis of eight cohort studies in Japan. Cancer science, 104(11), 1499–1507. https://doi.org/10.1111/cas.12241

Tseng, H. W., Shiue, Y. L., Tsai, K. W., Huang, W. C., Tang, P. L., & Lam, H. C. (2016). Risk of skin cancer in patients with diabetes mellitus: A nationwide retrospective cohort study in Taiwan. Medicine, 95(26), e4070. https://doi.org/10.1097/MD.0000000000004070

Wotton, C. J., Yeates, D. G., & Goldacre, M. J. (2011). Cancer in patients admitted to hospital with diabetes mellitus aged 30 years and over: record linkage studies. Diabetologia, 54(3), 527–534. https://doi.org/10.1007/s00125-010-1987-2

Brownlee M. (2001). Biochemistry and molecular cell biology of diabetic complications. Nature, 414(6865), 813–820. https://doi.org/10.1038/414813a

Adams, T. E., McKern, N. M., & Ward, C. W. (2004). Signalling by the type 1 insulin-like growth factor receptor: interplay with the epidermal growth factor receptor. Growth factors (Chur, Switzerland), 22(2), 89–95. https://doi.org/10.1080/08977190410001700998

Vicentini, M., Ballotari, P., Venturelli, F., Ottone, M., Manicardi, V., Gallo, M., Greci, M., Pinotti, M., Pezzarossi, A., & Giorgi Rossi, P. (2022). Impact of Insulin Therapies on Cancer Incidence in Type 1 and Type 2 Diabetes: A Population-Based Cohort Study in Reggio Emilia, Italy. Cancers, 14(11), 2719. https://doi.org/10.3390/cancers14112719

Chen, C. J., You, S. L., Lin, L. H., Hsu, W. L., & Yang, Y. W. (2002). Cancer epidemiology and control in Taiwan: a brief review. Japanese journal of clinical oncology, 32 Suppl, S66–S81. https://doi.org/10.1093/jjco/hye138

Chiang, C. J., Chen, Y. C., Chen, C. J., You, S. L., Lai, M. S., & Taiwan Cancer Registry Task Force (2010). Cancer trends in Taiwan. Japanese journal of clinical oncology, 40(10), 897–904. https://doi.org/10.1093/jjco/hyq057

Eisemann, N., Waldmann, A., Geller, A. C., Weinstock, M. A., Volkmer, B., Greinert, R., Breitbart, E. W., & Katalinic, A. (2014). Non-melanoma skin cancer incidence and impact of skin cancer screening on incidence. The Journal of investigative dermatology, 134(1), 43–50. https://doi.org/10.1038/jid.2013.304

Urban, K., Mehrmal, S., Uppal, P., Giesey, R. L., & Delost, G. R. (2021). The global burden of skin cancer: A longitudinal analysis from the Global Burden of Disease Study, 1990-2017. JAAD international, 2, 98–108. https://doi.org/10.1016/j.jdin.2020.10.013

Tang, H., Yang, K., Song, Y., & Han, J. (2018). Meta-analysis of the association between sodium-glucose co-transporter-2 inhibitors and risk of skin cancer among patients with type 2 diabetes. Diabetes, obesity & metabolism, 20(12), 2919–2924. https://doi.org/10.1111/dom.13474

Nwabudike, L. C., Oproiu, A. M., Dogaru, I. M., Costache, M., Onisor, C., & Tatu, A. L. (2021). Therapy Delayed is Therapy Denied: A Case Report of Melanoma Misdiagnosed as Diabetic Foot Ulcer. Clinical, cosmetic and investigational dermatology, 14, 1909–1912. https://doi.org/10.2147/CCID.S337545

Pradhan, R., Yu, O. H. Y., Platt, R. W., & Azoulay, L. (2023). Dipeptidyl peptidase-4 inhibitors and the risk of skin cancer among patients with type 2 diabetes: a UK population-based cohort study. BMJ open diabetes research & care, 11(6), e003550. https://doi.org/10.1136/bmjdrc-2023-003550

Ren, M. Y., Shi, Y. J., Lu, W., Fan, S. S., Tao, X. H., & Ding, Y. (2023). Facial Merkel cell carcinoma in a patient with diabetes and hepatitis B: A case report. World journal of clinical cases, 11(17), 4179–4186. https://doi.org/10.12998/wjcc.v11.i17.4179

Pradhan, R., Yu, O. H. Y., Platt, R. W., & Azoulay, L. (2024). Glucagon like peptide-1 receptor agonists and the risk of skin cancer among patients with type 2 diabetes: Population-based cohort study. Diabetic medicine : a journal of the British Diabetic Association, 41(4), e15248. https://doi.org/10.1111/dme.15248

Hill-Briggs, F., Adler, N. E., Berkowitz, S. A., Chin, M. H., Gary-Webb, T. L., Navas-Acien, A., Thornton, P. L., & Haire-Joshu, D. (2020). Social Determinants of Health and Diabetes: A Scientific Review. Diabetes care, 44(1), 258–279. Advance online publication. https://doi.org/10.2337/dci20-0053

Harvey, V. M., Patel, H., Sandhu, S., Wallington, S. F., & Hinds, G. (2014). Social determinants of racial and ethnic disparities in cutaneous melanoma outcomes. Cancer control : journal of the Moffitt Cancer Center, 21(4), 343–349. https://doi.org/10.1177/107327481402100411

Busek, P., Duke-Cohan, J. S., & Sedo, A. (2022). Does DPP-IV Inhibition Offer New Avenues for Therapeutic Intervention in Malignant Disease Cancers, 14(9), 2072. https://doi.org/10.3390/cancers14092072

Kuo, P. T., Zeng, Z., Salim, N., Mattarollo, S., Wells, J. W., & Leggatt, G. R. (2018). The Role of CXCR3 and Its Chemokine Ligands in Skin Disease and Cancer. Frontiers in medicine, 5, 271. https://doi.org/10.3389/fmed.2018.00271

FDA Briefing Document: Endocrinologic and Metabolic Drugs Advisory Committee Meeting (EMDAC): Liraglutide-LEADER. 2017.

Ederaine, S. A., Dominguez, J. L., Harvey, J. A., Mangold, A. R., Cook, C. B., Kosiorek, H., Buras, M., Coppola, K., & Karlin, N. J. (2021). Survival and glycemic control in patients with co-existing squamous cell carcinoma and diabetes mellitus. Future science OA, 7(5), FSO683. https://doi.org/10.2144/fsoa-2020-0150

Becker, J. C., Stang, A., Hausen, A. Z., Fischer, N., DeCaprio, J. A., Tothill, R. W., Lyngaa, R., Hansen, U. K., Ritter, C., Nghiem, P., Bichakjian, C. K., Ugurel, S., & Schrama, D. (2018). Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEC. Cancer immunology, immunotherapy : CII, 67(3), 341–351. https://doi.org/10.1007/s00262-017-2099-3

Bradford, P. T., Goldstein, A. M., McMaster, M. L., & Tucker, M. A. (2009). Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005. Archives of dermatology, 145(4), 427–434. https://doi.org/10.1001/archdermatol.2008.609

Arrington, J. H., 3rd, Reed, R. J., Ichinose, H., & Krementz, E. T. (1977). Plantar lentiginous melanoma: a distinctive variant of human cutaneous malignant melanoma. The American journal of surgical pathology, 1(2), 131–143.

Downloads

Published

2024-06-18

How to Cite

Juwita, T. A. ., & Siregar, I. S. . (2024). THE ANALYSIS STUDY OF ASSOCIATION OF TYPE 2 DIABETES MELLITUS AND SKIN CANCER : A COMPREHENSIVE SYSTEMATIC REVIEW. Journal of Advanced Research in Medical and Health Science (ISSN 2208-2425), 10(6), 113-121. https://doi.org/10.61841/xdw7fm80